PE20160156A1 - Derivados de prodroga de triazolpiridinas sustituidas - Google Patents

Derivados de prodroga de triazolpiridinas sustituidas

Info

Publication number
PE20160156A1
PE20160156A1 PE2015002605A PE2015002605A PE20160156A1 PE 20160156 A1 PE20160156 A1 PE 20160156A1 PE 2015002605 A PE2015002605 A PE 2015002605A PE 2015002605 A PE2015002605 A PE 2015002605A PE 20160156 A1 PE20160156 A1 PE 20160156A1
Authority
PE
Peru
Prior art keywords
alkyl
derivatives
triazolpyridines
prodrog
substituted
Prior art date
Application number
PE2015002605A
Other languages
English (en)
Inventor
Ulrich Lucking
Michael Bruning
Detlef Stockigt
Dirk Kosemund
Ursula Krenz
Gerhard Siemeister
Antje Margret Wengner
Donald Bierer
Hans-Georg Lerchen
Volker Schulze
Ildiko Terebesi
Philip Lienau
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of PE20160156A1 publication Critical patent/PE20160156A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052Val-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS SUSTITUIDOS DE 2-ANILINO-6-(4-{[(2R)-2-(4-FLUOROFENIL)PROPANOIL]AMINO}FENIL)[1, 2, 4]TRIAZOLO[1, 5-A]PIRIDINA DE FORMULA (I), EN DONDE RA ES -C(O)-(CH2)3-NH-C1-C6-ALQUILO, -C(O)O-(CH2)2-NH-C1-C6-ALQUILO, O -C(O)O-CH2-O-C(O)-C1-C6-ALQUILO, ENTRE OTROS; R1 ES METOXI O 2, 2, 2-TRIFLUOROETOXI; Y R2 ES -S(O)2-CH3, AZETIDIN-1-IL-CARBONILO, 3-FLUOROAZETIDIN-1-IL-CARBONILO O -C(O)-N(CH3)2. DICHOS COMPUESTOS SON INHIBIDORES DE LA QUINASA MPS-1, POR LO CUAL SON UTILES EN LA TERAPIA DE ENFERMEDADES RELACIONADAS CON UN CRECIMIENTO, PROLIFERACION O SUPERVIVENCIA CELULAR DESCONTROLADA, O CON UNA RESPUESTA INMUNE CELULAR INAPROPIADA, O CON UNA RESPUESTA INFLAMATORIA CELULAR INAPROPIADA, TALES COMO LAS LEUCEMIAS, LINFOMAS MALIGNOS, TUMORES CEREBRALES, TUMORES DE LAS CELULAS PULMONARES, ENTRE OTRAS
PE2015002605A 2013-06-11 2014-06-06 Derivados de prodroga de triazolpiridinas sustituidas PE20160156A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13171508 2013-06-11

Publications (1)

Publication Number Publication Date
PE20160156A1 true PE20160156A1 (es) 2016-04-20

Family

ID=48576905

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002605A PE20160156A1 (es) 2013-06-11 2014-06-06 Derivados de prodroga de triazolpiridinas sustituidas

Country Status (35)

Country Link
US (1) US9586958B2 (es)
EP (1) EP3008062B1 (es)
JP (1) JP2016526534A (es)
KR (1) KR20160019492A (es)
CN (1) CN105377848A (es)
AP (1) AP2015008898A0 (es)
AR (1) AR096585A1 (es)
AU (1) AU2014280356A1 (es)
CA (1) CA2914745A1 (es)
CL (1) CL2015003605A1 (es)
CR (1) CR20150659A (es)
CU (1) CU20150176A7 (es)
DK (1) DK3008062T3 (es)
DO (1) DOP2015000299A (es)
EA (1) EA201600002A1 (es)
ES (1) ES2626790T3 (es)
HK (1) HK1221955A1 (es)
HR (1) HRP20170717T1 (es)
HU (1) HUE033131T2 (es)
IL (1) IL242847A0 (es)
LT (1) LT3008062T (es)
MA (1) MA38654B1 (es)
MX (1) MX2015017119A (es)
NI (1) NI201500176A (es)
PE (1) PE20160156A1 (es)
PH (1) PH12015502746A1 (es)
PL (1) PL3008062T3 (es)
PT (1) PT3008062T (es)
RS (1) RS56034B1 (es)
SG (1) SG11201509858QA (es)
SI (1) SI3008062T1 (es)
TN (1) TN2015000545A1 (es)
UY (1) UY35610A (es)
WO (1) WO2014198647A2 (es)
ZA (1) ZA201508868B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41136A (fr) * 2014-12-09 2017-10-17 Bayer Pharma AG Composés pour le traitement d'un cancer
KR20180011089A (ko) 2015-04-17 2018-01-31 네덜런즈 트랜슬레이셔널 리서치 센터 비.브이. Ttk 억제제 화학요법을 위한 예후 바이오마커
NZ747259A (en) 2016-04-04 2022-11-25 Chemocentryx Inc Soluble c5ar antagonists
WO2023113478A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Methods of treating neoplastic diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2263566C (en) 1996-08-28 2003-09-09 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
SK158099A3 (en) 1997-05-28 2000-06-12 Rhone Poulenc Rorer Pharma Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JP2004346016A (ja) 2003-05-22 2004-12-09 Otsuka Chemical Co Ltd トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤
CA2530679A1 (en) 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds for treating angiogenesis
JP2008515874A (ja) 2004-10-07 2008-05-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌薬
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
EA200870592A1 (ru) 2006-05-31 2009-08-28 Галапагос Н.В. Триазолопиразиновые соединения, пригодные для лечения дегенеративных и воспалительных заболеваний
EP2056829B9 (en) 2006-08-16 2012-09-26 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
BRPI0716239A2 (pt) 2006-08-30 2013-08-13 Cellzome Ltd derivados de triazol como inibidores de cinase
JP2010526823A (ja) 2007-05-10 2010-08-05 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pi3キナーゼ阻害物質としてのキノキサリン誘導体
CN101801966A (zh) 2007-07-18 2010-08-11 诺瓦提斯公司 双环杂芳基化合物和它们作为激酶抑制剂的用途
JP2010535804A (ja) 2007-08-09 2010-11-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pi3キナーゼ阻害薬としてのキノキサリン誘導体
EA201000341A1 (ru) 2007-08-23 2010-10-29 Астразенека Аб 2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений
EP2181112A1 (en) 2007-08-31 2010-05-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2706578A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as pi3k inhibitors
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
PE20120110A1 (es) 2009-02-13 2012-02-20 Fovea Pharmaceuticals [1,2,4]triazolo[1,5-a]piridinas como inhibidores de cinasa
US8729082B2 (en) 2009-04-29 2014-05-20 Bayer Intellectual Property Gmbh Substituted imidazoquinoxalines
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2473498A1 (en) 2009-09-04 2012-07-11 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
ES2512840T3 (es) 2010-01-15 2014-10-24 Janssen Pharmaceuticals, Inc. Derivados de triazol bicíclicos sustituidos novedosos como moduladores de gamma-secretasa
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
WO2012143329A1 (en) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
ES2605946T3 (es) 2012-03-14 2017-03-17 Bayer Intellectual Property Gmbh Imidazopiridazinas sustituidas
PE20150354A1 (es) * 2012-07-10 2015-03-21 Bayer Pharma AG Metodos para preparar triazolopiridinas sustituidas
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
WO2014195276A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
AU2014280395A1 (en) * 2013-06-10 2015-12-17 Bayer Pharma Aktiengesellschaft Novel compounds for the treatment of cancer
KR20160018534A (ko) * 2013-06-11 2016-02-17 바이엘 파마 악티엔게젤샤프트 Mps-1 키나제 억제제 및 유사분열 억제제를 포함하는 암의 치료를 위한 조합물

Also Published As

Publication number Publication date
AR096585A1 (es) 2016-01-20
CR20150659A (es) 2016-01-29
ES2626790T3 (es) 2017-07-26
MX2015017119A (es) 2016-04-06
CN105377848A (zh) 2016-03-02
EP3008062B1 (en) 2017-04-05
HRP20170717T1 (hr) 2017-07-28
ZA201508868B (en) 2017-08-30
SI3008062T1 (sl) 2017-06-30
EA201600002A1 (ru) 2016-06-30
UY35610A (es) 2015-01-30
CL2015003605A1 (es) 2016-06-24
AU2014280356A1 (en) 2015-12-24
HUE033131T2 (en) 2017-11-28
NI201500176A (es) 2016-01-06
WO2014198647A2 (en) 2014-12-18
US9586958B2 (en) 2017-03-07
WO2014198647A3 (en) 2015-02-05
PT3008062T (pt) 2017-06-07
MA38654B1 (fr) 2018-11-30
JP2016526534A (ja) 2016-09-05
DK3008062T3 (en) 2017-06-12
IL242847A0 (en) 2016-02-01
TN2015000545A1 (en) 2017-04-06
DOP2015000299A (es) 2016-03-15
HK1221955A1 (zh) 2017-06-16
US20160207915A1 (en) 2016-07-21
EP3008062A2 (en) 2016-04-20
PL3008062T3 (pl) 2017-08-31
CA2914745A1 (en) 2014-12-18
RS56034B1 (sr) 2017-09-29
SG11201509858QA (en) 2015-12-30
PH12015502746A1 (en) 2016-03-21
CU20150176A7 (es) 2016-05-30
AP2015008898A0 (en) 2015-12-31
LT3008062T (lt) 2017-06-12
KR20160019492A (ko) 2016-02-19

Similar Documents

Publication Publication Date Title
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
CL2019000902A1 (es) Compuestos de benzo[b]tiofeno como agonistas de sting.
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
CO2018002829A2 (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm)
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
EA202090291A2 (ru) Производные бипиразола в качестве ингибиторов jak
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
AR095347A1 (es) Compuestos orgánicos
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
PE20090506A1 (es) DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4
PE20170663A1 (es) Compuestos de 5- cloro- 2- difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
ECSP13012596A (es) Proceso de elaboración para derivados de pirimidina
PE20160156A1 (es) Derivados de prodroga de triazolpiridinas sustituidas
MD20150073A2 (ro) Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK)
NI200700058A (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteína quinasa
PE20130012A1 (es) Derivados de pirazol como inhibidores de jak
PH12020550143A1 (en) Salts of pyrrolotriazine derivatives useful as tam inhibitors
GT201600091A (es) Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos
AR102171A1 (es) Compuestos sustituidos de aminopurina, sus composiciones y su uso en el tratamiento o prevención de melanoma
NZ596571A (en) Pyrazolopyrimidines and related heterocycles as kinase inhibitors
PE20160747A1 (es) Derivados heterociclicos inhibidores de la quinasa mps-1
PE20141351A1 (es) Triazolopiridinas
EA201390010A1 (ru) Замещенные триазолопиридины
DOP2016000127A (es) Inhibidores de quinasa relacionada con la tropomiosina (trk).
EA201891772A1 (ru) Трифторацетатная соль агониста tlr7 и ее кристаллическая форма b, способы получения и использование

Legal Events

Date Code Title Description
FD Application declared void or lapsed